ACRX / AcelRx Pharmaceuticals, Inc. (ACRX) CEO Vincent Angotti on Q4 2021 Results - Earnings Call Transcript

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Raffi Asadorian – Chief more_horizontal

AcelRx Pharmaceuticals (ACRX) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares more_horizontal

AcelRx Pharmaceuticals (ACRX) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares t more_horizontal

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Raffi Asadorian - Chief Fina more_horizontal

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of -900% and 97.04%, respectively, for the quarter ended December 2022. Do the more_horizontal

HAYWARD, Calif. , March 21, 2023 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the devel more_horizontal

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX ) Q3 2022 Results Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Raffi Asadorian more_horizontal

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 21.67% and 7.82%, respectively, for the quarter ended September 2022. Do the more_horizontal